Astaxanthin has the ability to significantly lower systolic blood pressure in rats, according to a new study performed at Georgetown University Medical Center.
Astaxanthin has the ability to significantly lower systolic blood pressure in rats, according to a new study performed at Georgetown University Medical Center. This study joins three other past studies performed at the Toyama Medical and Pharmaceutical University in Japan which researched astaxanthin’s ability to reduce hypertension as well mechanism of actions for this benefit.
In the Georgetown University study, tests suggested that the Renin-Angiotensin system was involved in the ability of astaxanthin to lower blood pressure. Also, at higher dosage levels it was shown that astaxanthin influenced circulating TNF-α and MCP-1 and lessened fat oxidation in the liver and kidneys. This is an indication that astaxanthin may help to reduce stress.
The study was sponsored by Fuji Chemical Industry (Japan) and performed using AstaREAL astaxanthin.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.